DPD status and fluoropyrimidines-based treatment: high activity matters too

Por Chamorey, Emmanuel, Francois, Eric, Etienne, Marie-Christine, Ferrero, Jean-Marc, Peyrade, Frederic, Barranger, Emmanuel, Bozec, Alexandre, Largillier, Rémy, Cassuto, Ophelie, Viotti, Julien, Schiappa, Renaud, Milano, Gérard
Publicado no BMC Cancer (2020)

All tyrosine kinase inhibitor-resistant chronic myelogenous cells are highly sensitive to Ponatinib

Por Cassuto, Ophélie, Dufies, Maeva, Jacquel, Arnaud, Robert, Guillaume, Ginet, Clémence, Dubois, Alix, Hamouda, Amine, Puissant, Alexandre, Luciano, Fredéric, Karsenti, Jean-Michel, Legros, Laurence, Cassuto, Jill Patrice, Lenain, Pascal, Auberger, Patrick
Publicado em 2012

Nous devons respecter le schéma vaccinal anti-SARS-CoV-2 sans décalage chez les patients atteints de cancer sous traitement

Por Barrière, Jérôme, Audigier-Valette, Clarisse, Borchiellini, Delphine, Hoch, Benjamin, Castelnau, Olivier, Francois, Eric, Gastaud, Lauris, Skaf, Richard, Berdah, Jean-François, Marie, Wislez, Lescaut, Willy, Peyrade, Frédéric, Cluzeau, Thomas, Cassuto, Ophélie, Carles, Michel
Publicado no Bull Cancer (2021)

CXCL7 is a predictive marker of sunitinib efficacy in clear cell renal cell carcinomas

Por Dufies, Maeva, Giuliano, Sandy, Viotti, Julien, Borchiellini, Delphine, Cooley, Linsay S, Ambrosetti, Damien, Guyot, Mélanie, Ndiaye, Papa Diogop, Parola, Julien, Claren, Audrey, Schiappa, Renaud, Gal, Jocelyn, Frangeul, Antoine, Jacquel, Arnaud, Cassuto, Ophélie, Grépin, Renaud, Auberger, Patrick, Bikfalvi, Andréas, Milano, Gérard, Escudier, Bernard, Rioux-Leclercq, Nathalie, Porta, Camillo, Negrier, Sylvie, Chamorey, Emmanuel, Ferrero, Jean-Marc, Pagès, Gilles
Publicado no Br J Cancer (2017)